Full-Time

Investment Banking Vice President

Healthcare Biopharma

Piper Sandler

Piper Sandler

1,001-5,000 employees

Compensation Overview

$250k/yr

+ Annual Incentive

New York, NY, USA

In Person

Category
Finance & Banking (1)
Required Skills
Investment Banking
Financial Modeling
Requirements
  • Minimum 6 years of investment banking experience or MBA degree and 3+ years of investment banking or closely related experience
  • Meaningful Mergers and Acquisitions transaction experience required
  • Ability to lead junior bankers throughout a transaction; includes reviewing work, setting expectations and providing constructive feedback
  • Deep understanding and passion for healthcare, biotechnology, biopharma or other relevant work experience
  • Highly motivated, team player with strong attention to detail and an ability to learn in a fast-paced environment
Responsibilities
  • Client Engagement: Serve as a key contact for select clients, fostering impactful relationships and contributing to client coverage
  • Marketing & Client Materials: Develop compelling marketing materials for company sale and financing assignments
  • Due Diligence: Actively participate in due diligence processes and drafting sessions for public offerings
  • Business Development: Assume increasing responsibilities in new business development initiatives over time
  • Transaction Execution: Lead and support the execution of M&A, equity, equity-linked, and debt transactions
  • Financial Analysis: Prepare comprehensive strategic and M&A analyses, detailed company valuations, and financial models
Desired Qualifications
  • BA/BS/MS or an advanced degree in life sciences (MD, PharmD, PhD) is a plus
  • Business writing skills, including the ability to write compelling selling memoranda and presentations
  • Strong knowledge of accounting and M&A deal modeling experience
  • Client management skills including ability to build relationships and establish trust with internal and external stakeholders
  • Exceptional work ethic and a high level of enthusiasm, initiative and leadership potential

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Minneapolis, Minnesota

Founded

1895

Simplify Jobs

Simplify's Take

What believers are saying

  • Tenth consecutive quarter of year-over-year revenue growth reaching record $470 million.
  • Corporate investment banking revenues surged 30% year-over-year to $324 million record.
  • Operating margin expanded to 20% as operating income grew 37% year-over-year.

What critics are saying

  • Healthcare franchise over-reliance collapses if FDA accelerates AI-driven drug approvals.
  • Talent drain to Wells Fargo and Goldman Sachs erodes mid-market M&A ranking.
  • Merchant banking investments like Paragon 28 dilute shareholder value amid cooling M&A.

What makes Piper Sandler unique

  • Ranked #2 in US mid-market M&A deals under $2 billion with record healthcare revenues.
  • Expanded to record 192 investment banking managing directors with specialized healthcare expertise.
  • Bookrunner on all 23 biopharma equity deals priced in Q1 2026.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Piper Sandler who can refer or advise you

Benefits

Wellness Program

Company News

Yahoo Finance
Apr 14th, 2026
Piper Sandler downgrades SAP, Asana and Monday.com as AI transition strains software sector

Piper Sandler has downgraded several enterprise software stocks as companies struggle to monetise artificial intelligence amid macroeconomic pressures. Germany's SAP was cut to "neutral" from "overweight", with its price target reduced to €170 from €220, citing slower-than-expected cloud conversions as chief information officers prioritise AI adoption over traditional ERP migrations. SAP's significant exposure to Europe, the Middle East and Africa — approximately 46% of fiscal 2025 revenue — leaves it vulnerable to regional economic pressures. Analysts noted the sector is undergoing a "SaaS to AI transition" on a compressed timeline, with meaningful AI revenue contributions expected to take time. Collaboration software firms Asana and Monday.com were also downgraded to "neutral", with price targets of $7 and $85 respectively, facing slowing seat expansion and moderating growth.

SGB Online
Apr 9th, 2026
Crocs' former IR chief joins Helly Hansen as Head of Finance and Operations.

Crocs' former IR chief joins Helly Hansen as Head of Finance and Operations. April 9, 2026 Kontoor Brands Inc. (KTB) reports that Erinn Murphy, formerly at Crocs, will join the company in early May as VP and global head of Finance and Operations for Helly Hansen and corporate investor relations. As a member of Helly Hansen's leadership team, Murphy will take an international assignment in Oslo, Norway, overseeing KTB's corporate investor relations. Murphy joins Kontoor from Crocs Inc., where she served as senior vice president, Investor Relations and Corporate Strategy. Prior to that, Murphy served as managing director of Consumer Equity Capital Markets for Piper Sandler. She was recently appointed to the board of Revolve Group, Inc. Murphy's appointment coincides with an expanded role for Michael Karapetian, who will serve as vice president of Global Brand and Operations Finance and Corporate Investor Relations, with responsibility for Global Brand and Supply Chain Finance and corporate investor relations. Karapetian will return from his international assignment at Helly Hansen in the third quarter of 2026 to allow for a transition period. The hiring of Murphy was announced a day after Kontoor reported that Joseph Alkire, who, in addition to his responsibilities as chief financial officer and global head of operations, will assume global responsibilities for the Helly Hansen brand, effective immediately. Børre Hegbom will continue as SVP and Global Head of Helly Hansen. Formerly Helly Hansen's managing director of Sport, Hegbom was promoted to that role last October. Kontoor, which also owns Wrangler and Lee, acquired Helly Hansen in June 2025. Images courtesy Helly Hansen and Crocs, Inc.

Yahoo Finance
Mar 30th, 2026
Piper Sandler initiates coverage on Dime Community Bancshares with $37 target and overweight rating

Piper Sandler initiated coverage of Dime Community Bancshares, Inc. (NASDAQ:DCOM) with an Overweight rating and a $37 price target on 16 March. The firm expects continued recovery in net interest margin, supported by significant loan repricing over 2026 and 2027. During the Q4 2025 earnings call, CEO Stuart Lubow reported core earnings per share of $0.79, up 88% year-on-year, driven by record quarterly revenue of $124 million. Core deposits increased by $1.2 billion year-on-year, whilst business loans rose over $500 million compared to the prior year. Dime Community Bancshares operates through its subsidiary, Dime Community Bank, providing commercial and consumer banking services. The company is targeting an efficiency ratio below 50% for 2026.

Business Wire
Mar 27th, 2026
Secretome Therapeutics announces participation in upcoming investor conferences.

Secretome Therapeutics announces participation in upcoming investor conferences. PLANO, Texas-(BUSINESS WIRE)-Secretome Therapeutics, a clinical-stage biotechnology company developing novel cellular and cell-based therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced its participation in three upcoming investor conferences and meetings focused on the biopharma sector. Secretome is scheduled to participate in Guggenheim Securities' Healthcare Private Biopharma Company Virtual 1x1 Day on March 31, 2026, and Piper Sandler's Spring Biopharma Symposium in Boston on April 15-16, 2026. "These invitations reflect growing interest in Secretome's platform and development strategy as we continue advancing STM-01 and our broader pipeline," said Vinny Jindal. "We appreciate the opportunity to engage with investors and industry participants as we work to bring novel therapies forward for patients with serious unmet medical needs." Secretome is advancing STM-01 for Duchenne muscular dystrophy-associated cardiomyopathy (DMD-CM), the lead indication for the company's flagship program.Secretome expects to initiate Phase 2 in the second quarter of 2026 and is concurrently preparing for its pivotal Phase 3 program. About Secretome Therapeutics Secretome Therapeutics is a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells (nCPCs) for orphan and underserved chronic diseases. Its lead program, STM-01, is being advanced for Duchenne muscular dystrophy-associated cardiomyopathy (DMD-CM), alongside a broader pipeline of nCPC-based therapeutic programs. Forward-Looking Statements This press release contains forward-looking statements, including statements regarding anticipated conference participation, future corporate updates, development timing, and planned clinical and regulatory milestones. Actual results may diXer materially from those expressed or implied by these forward-looking statements due to a variety of risks and uncertainties.

Paragon 28
Mar 26th, 2026
Paragon 28 Completes Series B Financing with Piper Sandler Merchant Banking and MVM Partners

Paragon 28, Inc., a leading orthopedic foot and ankle company, today announced the completion of a Series B financing.  The round was co-led by Piper Sandler Merchant Banking, a commercial stage growth equity investment business of Piper Sandler Companies, and MVM Partners, a healthcare growth equity investment firm.  The financing also included participation from an existing Series A investor. Read the full article here.